Silybum marianum/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases alanine aminotransferase
StrongEvidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding.Finding“The pooled results from the 59 arms including 3313 patients showed a significant reduction in serum ALT levels following the administration of silymarin, with SMD (95% CI): − 0.912 (− 1.177, − 0.646), prediction interval of PI (95% CI): − 0.912 (− 2.906, 1.082) and p-value of 0.000.”
Quoted verbatim from Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury.. - Study
- meta-analysis
- Participants
- 3,313
- Dose
- Pooled across trials, daily doses from about 140 mg to 1050 mg
- Population
- Patients with liver disease of various causes and some other conditions, pooled across randomized trials (59 arms)
Effect -0.912 standardised mean difference, 95% CI -1.177 to -0.646
Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury.2025PMID:40221681Permalink
Keep reading
- Everything the graph holds on Silybum marianum
- Every compound studied against Alanine aminotransferase
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4Q58J6Y959HB6XPMX5KF8Z8